No BGXX <> US Cannabis Readthrough; Uplisting will separate the wheat from the chaff

by | Jun 6, 2022 | Comp Table & Market Commentary, Company Analysis

You may have heard about the roller coaster direct listing (NOT an IPO) of Bright Green Corp (BGXX), a company that plans to cultivate cannabis for pharmaceutical research under a license from the DEA.

This has little read through to the rest of the US cannabis operators, and its wild stock moves are not indicative of anything for the rest of the US cannabis industry – neither today nor if they uplist to major exchanges.

Source: Sentieo

The following article also discusses the true benefit of uplisting to NASDAQ for US cannabis companies, looks at why fundamentals matter even more after uplisting, and ends with a cautionary tale from Canada…